Literature DB >> 19413677

Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

M E Sarasquete1, M González, J F San Miguel, R García-Sanz.   

Abstract

The objectives of this study were to review epidemiological, clinical and biological aspects associated with the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in multiple myeloma (MM) patients, with special emphasis on the genetic aspects. A detailed review of previously described risk factors as well as recent genetic findings mostly comprises this work. The most recent meeting abstracts and relevant articles published in journals covered by the Science Citation Index and Medline are also examined. The review pays special attention to the genetic component of BRONJ. A total of 15 series and 14 guidelines or revisions were selected to fit the aims of the review. Gene variability was reviewed in depth to give a clinical illustration on the genetic aspects of BRONJ. Crude prevalence and 5-year cumulative incidence were considered as the most important end points for predictive purposes. Several acquired factors were recognized as predictors for BRONJ in MM, especially intravenous bisphosphonates, dental trauma and advanced age. Among genetic factors, polymorphisms on CYP2C8 gene arise as a promising risk factor. Bisphosphonate-related osteonecrosis of the jaw can be predicted with a conjunction of genetic and environmental risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19413677     DOI: 10.1111/j.1601-0825.2009.01568.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  11 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.

Authors:  F Lapi; F Cipriani; A P Caputi; G Corrao; A Vaccheri; M C Sturkenboom; M Di Bari; D Gregori; F Carle; T Staniscia; A Vestri; M Brandi; V Fusco; G Campisi; G Mazzaglia
Journal:  Osteoporos Int       Date:  2012-05-23       Impact factor: 4.507

3.  Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study.

Authors:  K Froelich; A Radeloff; C Köhler; R Mlynski; J Müller; R Hagen; N H Kleinsasser
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-02-16       Impact factor: 2.503

4.  Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians.

Authors:  Lana El Osta; Badi El Osta; Sara Lakiss; Martine Hennequin; Nada El Osta
Journal:  Support Care Cancer       Date:  2015-02-13       Impact factor: 3.603

Review 5.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

6.  Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review.

Authors:  Br Varun; Tt Sivakumar; Bindu J Nair; Anna P Joseph
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

7.  Viewpoints of dentists on the use of bisphosphonates in rheumatology patients.

Authors:  Coline Daron; Christophe Deschaumes; Martin Soubrier; Sylvain Mathieu
Journal:  Int Dent J       Date:  2018-02-15       Impact factor: 2.607

8.  Extensive protein expression changes induced by pamidronate in RAW 264.7 cells as determined by IP-HPLC.

Authors:  Sang Shin Lee; Soung Min Kim; Yeon Sook Kim; Suk Keun Lee
Journal:  PeerJ       Date:  2020-05-21       Impact factor: 2.984

9.  Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series.

Authors:  Guillermo Pardo-Zamora; Yanet Martínez; Jose Antonio Moreno; Antonio J Ortiz-Ruíz
Journal:  Int J Environ Res Public Health       Date:  2021-01-24       Impact factor: 3.390

10.  Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells.

Authors:  Viviana Ribeiro; Mónica Garcia; Raquel Oliveira; Pedro S Gomes; Bruno Colaço; Maria Helena Fernandes
Journal:  J Cell Mol Med       Date:  2013-10-31       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.